Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib maintenance versus observation after first-line chemotherapy for ovarian, primary peritoneal, or fallopian tube cancer
ACTRN12607000071426Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Erlotinib maintenance with Observation (2 arms). Primary endpoint: Progression-free survival. Started Oct 2005; status: completed.
02
Drugs
erlotinib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on ACTRN12607000071426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000071426.